Detalhe da pesquisa
1.
Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 95(5): 410-418, 2024 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37940409
2.
Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network.
J Neurol Neurosurg Psychiatry
; 94(1): 23-30, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36171104
3.
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial.
J Neurol Neurosurg Psychiatry
; 94(12): 1004-1011, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37414534
4.
Disability accrual in primary and secondary progressive multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 94(9): 707-717, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37068931
5.
RNA-Seq profiling of leukocytes reveals a sex-dependent global circular RNA upregulation in multiple sclerosis and 6 candidate biomarkers.
Hum Mol Genet
; 29(20): 3361-3372, 2020 12 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-33030201
6.
Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosis.
J Neuroinflammation
; 19(1): 277, 2022 Nov 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-36403026
7.
Confirmed disability progression as a marker of permanent disability in multiple sclerosis.
Eur J Neurol
; 29(8): 2321-2334, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35582938
8.
Circular RNA profiling reveals that circular RNAs from ANXA2 can be used as new biomarkers for multiple sclerosis.
Hum Mol Genet
; 26(18): 3564-3572, 2017 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28651352
9.
The First Dose of Fingolimod Affects Circulating Extracellular Vesicles in Multiple Sclerosis Patients.
Int J Mol Sci
; 19(8)2018 Aug 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-30126230
10.
DAT imaging and clinical biomarkers in relatives at genetic risk for LRRK2 R1441G Parkinson's disease.
Mov Disord
; 31(3): 335-43, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26686514
11.
Identification of ncRNAs as potential therapeutic targets in multiple sclerosis through differential ncRNA - mRNA network analysis.
BMC Genomics
; 16: 250, 2015 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-25880556
12.
Bacteria-Fungi Interactions in Multiple Sclerosis.
Microorganisms
; 12(5)2024 Apr 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38792701
13.
Detecting disability using self-reported and clinical assessments in early-stage relapsing-remitting multiple sclerosis: Looking for a complementary approach.
Mult Scler J Exp Transl Clin
; 9(2): 20552173231169475, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37187856
14.
Hopelessness in Patients with Early-Stage Relapsing-Remitting Multiple Sclerosis.
Patient Prefer Adherence
; 17: 1431-1439, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37337517
15.
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis.
JAMA Neurol
; 80(7): 702-713, 2023 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37437240
16.
Effectiveness and Safety of Teriflunomide in Relapsing-Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study.
Neurol Ther
; 12(6): 2177-2193, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37861931
17.
HLA-DRB1*15:01 and multiple sclerosis: a female association?
Mult Scler
; 18(5): 569-77, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22127897
18.
Microbial dysbiosis and lack of SCFA production in a Spanish cohort of patients with multiple sclerosis.
Front Immunol
; 13: 960761, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36325343
19.
Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology.
Mult Scler Relat Disord
; 63: 103805, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35512501
20.
Long-term prognosis communication preferences in early-stage relapsing-remitting multiple sclerosis.
Mult Scler Relat Disord
; 64: 103969, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35728432